V022-6105 Screening compound: 2-({5-[(4-fluorophenyl)methyl]-4-oxo-4H,5H,6H,7H,8H-pyrazolo[1,5-a][1,4]diazepin-2-yl}formamido)-N-[2-(morpholin-4-yl)ethyl]propanamide

V022-6105 Screening compound: 2-({5-[(4-fluorophenyl)methyl]-4-oxo-4H,5H,6H,7H,8H-pyrazolo[1,5-a][1,4]diazepin-2-yl}formamido)-N-[2-(morpholin-4-yl)ethyl]propanamide
V022-6105 Screening compound: 2-({5-[(4-fluorophenyl)methyl]-4-oxo-4H,5H,6H,7H,8H-pyrazolo[1,5-a][1,4]diazepin-2-yl}formamido)-N-[2-(morpholin-4-yl)ethyl]propanamide alternative view

Chemical Structure Depiction of ChemDiv screening compound V022-6105
2-({5-[(4-fluorophenyl)methyl]-4-oxo-4H,5H,6H,7H,8H-pyrazolo[1,5-a][1,4]diazepin-2-yl}formamido)-N-[2-(morpholin-4-yl)ethyl]propanamide

Available from 1 mg

Formats:

  • Glass Vials (4ml Glass Vials VWR #97047-678)
  • 96-tube racks (Matrix #4247 96-well 1.4ml sealed with capmats, empty cols 1 & 12, 100uL of 10mM)

Shiptime: 1 week worldwide delivery in most cases

Compound Identifiers

ChemDiv Compound ID

V022-6105

Molecular Formula

C24H31FN6O4 (C24 H31 FN6 O4)

Compound Name

2-({5-[(4-fluorophenyl)methyl]-4-oxo-4H,5H,6H,7H,8H-pyrazolo[1,5-a][1,4]diazepin-2-yl}formamido)-N-[2-(morpholin-4-yl)ethyl]propanamide

IUPAC name

2-({5-[(4-fluorophenyl)methyl]-4-oxo-4H5H6H7H8H-pyrazolo[15-a][14]diazepin-2-yl}formamido)-N-[2-(morpholin-4-yl)ethyl]propanamide

SMILES

CC(C(NCCN1CCOCC1)=O)NC(c1nn(CCCN(Cc(cc2)ccc2F)C2=O)c2c1)=O

InChI

InChI=1S/C24H31FN6O4/c1-17(22(32)26-7-10-29-11-13-35-14-12-29)27-23(33)20-15-21-24(34)30(8-2-9-31(21)28-20)16-18-3-5-19(25)6-4-18/h3-6,15,17H,2,7-14,16H2,1H3,(H,26,32)(H,27,33)/t17-/m0/s1

InChI Key

IDVGBGSSCWROML-KRWDZBQOSA-N

MDL Number (MFCD)

MFCD19907659

Chemical and Physical Properties

Saltdata

not_available

Molecular Weight

486.55

Hydrogen Bond Acceptors Count

9.00

Hydrogen Bond Donors Count

2.00

Rotatable Bond Count

10.00

Number of Nitrogen and Oxygen Atoms

10

Partition Coefficient, logP

0.086

Distribution Coefficient, logD

0.029

Water Solubility, LogSw

-1.96

Polar Surface Area

90.376

Acid Dissociation Constant (pKa)

12.22

Base Dissociation Constant (pKb)

6.55

Number of Chiral Centers

1.00

Percent sp3 carbon bonding

50.00

V022-6105 in Drug Discovery

Included in Screening Libraries

Allosteric Kinases Inhibitors Library (23117 compounds)

Anticancer Library (62698 compounds)

Antiviral HBV Library (10007 compounds)

Antiviral Library (67538 compounds)

Macl-GPIb alpha Interaction Library (22969 compounds)

PPI Helix Turn 3D-Mimetics Library (71298 compounds)

Protein-Protein Interaction Library (218420 compounds)

Alpha-Helix Mimetics Library (25899 compounds)

Included in 1.7M Stock Database

Therapeutical areas:
  • Cancer
  • Female
  • Congenital
  • Skin
  • Cancer
  • Antiviral
  • Infections
  • Immune system
  • Antiviral
  • Infections
  • Immune system
  • Hemic and lymphatic
  • Cardiovascular
Targets:
  • Kinases
Mechanism of action:
  • PPI modulators
  • PPI modulators
  • PPI modulators
Structure:
  • Mimetics
  • Mimetics

References: we are preparing a list of scientific research reports with V022-6105 chemical compound. It will be published here after verification.

Frequently Asked Questions

How to purchase chemical compound V022-6105?
Check Price and Availability of V022-6105, then you can add required amount to the Shopping Cart. In the Shopping Cart you can again refine your selection. Once you are sure that it’s exactly what you want you can move forward with the Checkout (to pay online by credit card, or via PayPal), or Request a Quote.
What is the minimum amount of V022-6105 you sell to drug discovery company or institution?
Available from 1 mg in Glass Vials or 96-tube racks.
Delivery options for V022-6105
ChemDiv sends parcels with Express services (UPS, WC).
  • 1–2 days for small orders
  • 2–4 weeks for large selections
Delivery formats for V022-6105
  • 0.5–50 mg of dry powder sample in single glass vials, custom vials
  • DMSO solutions frozen 10μl–250μl@10mM (96 and 384 format)

Custom synthesis of V022-6105 available by request